Barclays PLC Raises Stock Position in Royalty Pharma plc (NASDAQ:RPRX)

Barclays PLC increased its stake in shares of Royalty Pharma plc (NASDAQ:RPRX - Free Report) by 17.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 363,308 shares of the biopharmaceutical company's stock after purchasing an additional 54,421 shares during the period. Barclays PLC owned approximately 0.06% of Royalty Pharma worth $9,269,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently made changes to their positions in the stock. Keene & Associates Inc. raised its holdings in shares of Royalty Pharma by 1.9% during the fourth quarter. Keene & Associates Inc. now owns 19,420 shares of the biopharmaceutical company's stock valued at $495,000 after purchasing an additional 370 shares during the last quarter. National Bank of Canada FI raised its holdings in shares of Royalty Pharma by 21.8% during the fourth quarter. National Bank of Canada FI now owns 2,074 shares of the biopharmaceutical company's stock valued at $53,000 after purchasing an additional 371 shares during the last quarter. Blue Trust Inc. raised its holdings in shares of Royalty Pharma by 31.3% during the fourth quarter. Blue Trust Inc. now owns 1,579 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 376 shares during the last quarter. Sanctuary Advisors LLC raised its holdings in shares of Royalty Pharma by 0.9% during the fourth quarter. Sanctuary Advisors LLC now owns 41,854 shares of the biopharmaceutical company's stock valued at $1,068,000 after purchasing an additional 388 shares during the last quarter. Finally, Arizona State Retirement System raised its holdings in shares of Royalty Pharma by 0.5% during the fourth quarter. Arizona State Retirement System now owns 110,637 shares of the biopharmaceutical company's stock valued at $2,822,000 after purchasing an additional 537 shares during the last quarter. 54.35% of the stock is owned by hedge funds and other institutional investors.

Royalty Pharma Stock Performance

Shares of NASDAQ:RPRX traded up $0.34 during midday trading on Monday, hitting $32.54. The company had a trading volume of 3,256,591 shares, compared to its average volume of 3,259,800. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.44 and a quick ratio of 1.44. The company has a market cap of $18.76 billion, a price-to-earnings ratio of 22.44, a PEG ratio of 2.31 and a beta of 0.50. Royalty Pharma plc has a 12-month low of $24.05 and a 12-month high of $34.20. The company has a fifty day moving average of $32.52 and a two-hundred day moving average of $29.48.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, topping the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. On average, equities research analysts expect that Royalty Pharma plc will post 4.49 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th will be paid a $0.22 dividend. The ex-dividend date of this dividend is Friday, May 16th. This represents a $0.88 annualized dividend and a dividend yield of 2.70%. Royalty Pharma's dividend payout ratio (DPR) is 60.69%.

Wall Street Analysts Forecast Growth

Separately, Citigroup reissued a "buy" rating on shares of Royalty Pharma in a report on Friday, March 28th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $42.50.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.